🇺🇸 FDA
Patent

US 7118747

AT4 receptor ligands as angiogenic, anti-angiogenic, and anti-tumor agents

granted A61KA61K38/05A61K38/06

Quick answer

US patent 7118747 (AT4 receptor ligands as angiogenic, anti-angiogenic, and anti-tumor agents) held by Pacific Northwest Biotechnology Inc. expires Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Pacific Northwest Biotechnology Inc.
Grant date
Tue Oct 10 2006 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K38/05, A61K38/06, A61K38/07, A61K38/08